The New York Stock Exchange ended the session with Pfizer jumping 3.51% to $40.79 on Wednesday, after three consecutive sessions in a row of gains. The New York Stock Exchange jumped 0.29% to $14,188.20, following yesterday’s upward trend on what was a somewhat positive trend trading session today.

Pfizer today’s close was $40.79, 1.50% below its 52-week high of $41.40.

News about Pfizer today

Pfizer-biontech coronavirs vaccine gains approval for use in the UK. According to today’s article on ForexLive, “UK says that the vaccine will be made available starting from next week
This has been widely anticipated but it adds to the optimism and buzz surrounding vaccine developments.”

Pfizer says US FDA and EU EMA decisions on authorisation expected this month as well. According to today’s article on ForexLive, “Pfizer briefs after the UK MHRA authorises emergency-use supply for its coronavirus vaccine
The pharmaceutical firm also confirms that companies are ready to deliver the first doses to the UK immediately.”

Pfizer, biontech’s covid-19 vaccine wins u.k. authorization. According to today’s article on The Wall Street Journal, “Britain became the first Western nation to grant emergency-use authorization for a Covid-19 vaccine, clearing a shot developed by Pfizer and Germany’s BioNTech to be distributed in limited numbers within days..”

According to today’s article on The Wall Street Journal, “Salesforce.com, Pfizer, biontech” are stocks to watch today.

According to today’s article on Bloomberg Quint, “Vaccine-Tied Stocks Flail After U.K”

Pfizer’s Sales

Pfizer’s sales growth is a negative 9.7% for the current quarter and a decline by 9.1% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 12.7% and a negative 12.5%, respectively.

Pfizer’s Revenue

Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.

Pfizer’s Stock Top and Bottom Yearly Value

Pfizer’s stock is valued at $40.79 at 16:57 EST, below its 52-week high of $41.40 and way above its 52-week low of $26.45.

Pfizer’s Moving Average

Pfizer’s worth is way higher than its 50-day moving average of $35.78 and way higher than its 200-day moving average of $34.84.

Previous days news about Pfizer

According to yesterday’s article on Bloomberg Quint, “Pfizer, BioNTech Seek Clearance to Sell Covid Vaccine in Europe.”

According to yesterday’s article on Bloomberg Quint, “Pfizer, biontech seek EU clearance for covid-19 vaccine. ”

Pfizer-biontech seeks EU clearance for coronavirus vaccine. According to yesterday’s article on ForexLive, “Pfizer vaccine can be in use in the EU by the year-end if cleared.  Pfizer-BioNTech just announced that they have submitted an application to the EMA today to seek clearance for coronavirus vaccine use in the EU..”

Pfizer, biontech file for covid-19 vaccine approval in europe. According to yesterday’s article on The Wall Street Journal, “Pfizer and partner BioNTech said they are seeking approval from the European Union for their coronavirus vaccine.”

Pfizer, biontech apply for CMA in europe for covid-19 vaccine candidate. According to yesterday’s article on MarketWatch, “Shares of Pfizer Inc”

LEAVE A REPLY

Please enter your comment!
Please enter your name here